Latest Xintela News & Updates

See the latest news and media coverage for Xintela. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Xintela

Biopharma company developing stem cell and cancer therapies

xintela.se
Headquarters
Lund, Sweden
Founded year
2009
Company type
Public company
Number of employees
20–50

Latest news about Xintela

Company announcements

  • Xintela

    Xintela calls an annual general meeting

    The annual general meeting is held on May 22, 2026 in Lund. Proposed election of board of directors, auditor, no dividend and authorization for share issues.

  • Xintela

    Xintela is granted US patent for XSTEM

    The patent protects the treatment of hard-to-heal wounds and skin defects until 2043. It was developed with Linköping University Hospital.

  • Xintela

    Xintela publishes year-end report 2025

    Net sales fell to 2,282 KSEK for the full year. Result before tax was -50,158 KSEK. Targinta collaborates with MSK. Clinical study with XSTEM completed.

  • Xintela

    Xintela completes clinical study with XSTEM on hard-to-heal leg ulcers

    The company's phase I/IIa study on patients with venous leg ulcers has been completed. Final results on safety and tolerability will be reported at the end of May.

Unlock all announcements with a

Media coverage

  • FinanzNachrichten

    Xintela AB: Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

    Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company's stem cell...

  • Yahoo Finance

    Xintela AB (publ) (XINT.ST)

    Find the latest Xintela AB (publ) (XINT.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

  • MarketWatch

    Xintela AB

    Visit a quote page and your recently viewed tickers will be displayed here.

  • FinanzNachrichten

    Xintela AB: Last patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers

    Xintela (XINT) announces that the last patient has been dosed in the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg...

Unlock all articles with a

Never miss news about Xintela

Track Xintela and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Xintela competitors & trending companies

Browse news for competitors to Xintela and other trending companies.